SCHEMBL16276196

SCHEMBL16276196

O=C(Nc1nc2ccccc2s1)c1ccc(N(Cc2ccc(F)cc2)C(=O)[C@H]2O[C@@H]2C(=O)Nc2cccc(F)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.53
▸ RAB9A P51151 7/20 0.53
▸ KDM4E B2RXH2 5/20 0.53
▸ NFKB1 P19838 2/20 0.53
▸ NFKB2 Q00653 2/20 0.53
▸ RELA Q04206 2/20 0.53
▸ HTT P42858 1/20 0.53
▸ LRRK2 Q5S007 3/20 0.45
▸ LMNA P02545 2/20 0.43
▸ MEN1 O00255 5/20 0.43
▸ KMT2A Q03164 5/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ SCD O00767 6/20 0.42
▸ TOP1 P11387 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ TRPV1 Q8NER1 2/20 0.40
▸ MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16276157 0.93 NPC1 (0.51) NPC1RAB9AKDM4ENFKB1NFKB2
SCHEMBL16276105 0.93 NPC1 (0.51) NPC1RAB9AKDM4ENFKB1NFKB2
SCHEMBL16276192 0.93 NPC1 (0.57) NPC1RAB9AKDM4ENFKB1NFKB2
SCHEMBL16276371 0.92 NPC1 (0.51) NPC1RAB9AKDM4ENFKB1NFKB2
SCHEMBL16276155 0.92 NPC1 (0.52) NPC1RAB9AKDM4ENFKB1NFKB2
SCHEMBL17708494 0.90 NPC1 (0.51) NPC1RAB9AKDM4ENFKB1NFKB2
SCHEMBL16276348 0.89 NPC1 (0.53) NPC1RAB9AKDM4ENFKB1NFKB2
SCHEMBL17708488 0.89 KDM4E (0.53) NPC1RAB9AKDM4ENFKB1NFKB2
SCHEMBL16276301 0.87 NPC1 (0.55) NPC1RAB9AKDM4ENFKB1NFKB2
SCHEMBL16276111 0.87 NPC1 (0.60) NPC1RAB9AKDM4ENFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630957-B2 2,3-butanediamide epoxide compound and preparation method and use thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2017-04-25 — — US disclosed
US-20160115160-A1 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) 2016-04-28 — — US disclosed
WO-2014190899-A1 2,3-BUTANEDIAMIDE EPOXIDE COMPOUND AND PREPARATION METHOD AND USE THEREOF 中国人民解放军军事医学科学院毒物药物研究所 (CN) 2014-12-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115160-A1 2, 3-Butanediamide Epoxide Compound and Preparation Method and Use Thereof ECE2, GNE, EPHX2 NPC1 697/4885RAB9A 1370/4885KDM4E 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback